IPO league tables: Relypsa and Insys snag biotech boom top spots
This article was originally published in Scrip
Relypsa has snagged the top spot as the 2013 biopharma IPO debutant with the highest daily share price growth rate. It pipped to the post Insys Therapeutics, which showed the highest absolute growth since its IPO, but which had over six months more to reap the benefits of the biotech boom on the US public markets.
You may also be interested in...
Phase I data presented at ASCO for ALLO-501 offer proof of concept for the CD19 allogeneic CAR-T and a companion drug, ALLO-647, for lymphodepletion.
Dispatches from a world turned upside down covering a possible US government investigation into BARDA contracting practices and Medicare Part D plans waiving cost sharing for COVID-19 treatments.
The US FDA requests several manufacturers recall extended-release metformin based on studies confirming a higher NDMA impurity threshhold; previous testing found no significant risks.